Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
作者信息
Piccaluga Pier Paolo, Malagola Michele, Rondoni Michela, Amabile Marilina, Paolini Stefania, Soverini Simona, Gaitani Stavroula, Visani Giuseppe, Baccarani Michele, Martinelli Giovanni
出版信息
Eur J Haematol. 2004 Apr;72(4):302-3. doi: 10.1111/j.1600-0609.2004.00212.x.
Abstract
摘要
相似文献
1
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Eur J Haematol. 2004 Apr;72(4):302-3. doi: 10.1111/j.1600-0609.2004.00212.x.
2
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.伊马替尼（STI571）与异基因干细胞移植治疗Ph+难治性急性淋巴细胞白血病的良好疗效。
Bone Marrow Transplant. 2002 Dec;30(12):971-3. doi: 10.1038/sj.bmt.1703760.
3
Imatinib for relapsed BCR/ABL positive leukemias.伊马替尼用于复发的BCR/ABL阳性白血病。
Ann Hematol. 2002;81 Suppl 2:S36-7.
4
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.甲磺酸伊马替尼，一种BCR-ABL的选择性抑制剂，用于治疗慢性粒细胞白血病。
Expert Rev Anticancer Ther. 2007 Mar;7(3):249-51. doi: 10.1586/14737140.7.3.249.
5
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.甲磺酸伊马替尼（格列卫）是用于挽救治疗复发/难治性费城染色体阳性成人急性白血病的有效药物。
Hematology. 2003 Jun;8(3):139-43. doi: 10.1080/1024533031000134929.
6
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.成人费城染色体阳性急性淋巴细胞白血病中额外染色体异常及其预后意义：化疗中使用或不使用伊马替尼的情况
Ann Hematol. 2009 Nov;88(11):1069-77. doi: 10.1007/s00277-009-0720-z. Epub 2009 Mar 10.
7
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.伊马替尼与化疗联合治疗新诊断的BCR-ABL阳性急性淋巴细胞白血病的高完全缓解率及良好预后：日本成人白血病研究组的一项II期研究
J Clin Oncol. 2006 Jan 20;24(3):460-6. doi: 10.1200/JCO.2005.03.2177. Epub 2005 Dec 12.
8
9
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.在BCR-ABL阳性急性淋巴细胞白血病中，增加BCR-ABL表达水平和/或ABL点突变的出现并不总是能预测对甲磺酸伊马替尼的耐药性。
Leuk Res. 2009 Jul;33(7):e73-4. doi: 10.1016/j.leukres.2008.11.009. Epub 2008 Dec 23.
10
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.单中心300例接受伊马替尼治疗的BCR-ABL阳性白血病患者的反应与耐药情况：4.5年随访
Cancer. 2005 Apr 15;103(8):1659-69. doi: 10.1002/cncr.20922.
Zotero 插件